title: The combined transduction of copper, zinc-superoxide dismutase and catalase mediated by cell-penetrating peptide, PEP-1, to protect myocardium from ischemia-reperfusion injury.
abstract: BACKGROUND
  Our previous studies indicate that either PEP-1-superoxide dismutase 1 (SOD1) or PEP-1-catalase (CAT) fusion proteins protects myocardium from ischemia-reperfusion-induced injury in rats. The aim of this study is to explore whether combined use of PEP-1-SOD1 and PEP-1-CAT enhances their protective effects.
  
  
  METHODS
  SOD1, PEP-1-SOD1, CAT or PEP-1-CAT fusion proteins were prepared and purified by genetic engineering. In vitro and in vivo effects of these proteins on cell apoptosis and the protection of myocardium after ischemia-reperfusion injury were measured. Embryo cardiac myocyte H9c2 cells were used for the in vitro studies. In vitro cellular injury was determined by the expression of lactate dehydrogenase (LDH). Cell apoptosis was quantitatively assessed with Annexin V and PI double staining by Flow cytometry. In vivo, rat left anterior descending coronary artery (LAD) was ligated for one hour followed by two hours of reperfusion. Hemodynamics was then measured. Myocardial infarct size was evaluated by TTC staining. Serum levels of myocardial markers, creatine kinase-MB (CK-MB) and cTnT were quantified by ELISA. Bcl-2 and Bax expression in left ventricle myocardium were analyzed by western blot.
  
  
  RESULTS
  In vitro, PEP-1-SOD1 or PEP-1-CAT inhibited LDH release and apoptosis rate of H9c2 cells. Combined transduction of PEP-1-SOD1 and PEP-1-CAT, however, further reduced the LDH level and apoptosis rate. In vivo, combined usage of PEP-1-SOD1 and PEP-1-CAT produced a greater effect than individual proteins on the reduction of CK-MB, cTnT, apoptosis rate, lipoxidation end product malondialdehyde, and the infarct size of myocardium. Functionally, the combination of these two proteins further increased left ventricle systolic pressure, but decreased left ventricle end-diastolic pressure.
  
  
  CONCLUSIONS
  This study provided a basis for the treatment or prevention of myocardial ischemia-reperfusion injury with the combined usage of PEP-1-SOD1 and PEP-1-CAT fusion proteins.
authors: Institute of Clinical Medicine and Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
authors: Guang-Qing
authors: GQ
authors: Huang
authors: Jia-Ning
authors: JN
authors: Wang
authors: Jun-Ming
authors: JM
authors: Tang
authors: Lei
authors: L
authors: Zhang
authors: Fei
authors: F
authors: Zheng
authors: Jian-Ye
authors: JY
authors: Yang
authors: Ling-Yun
authors: LY
authors: Guo
authors: Xia
authors: X
authors: Kong
authors: Yong-Zhang
authors: YZ
authors: Huang
authors: Yong
authors: Y
authors: Liu
authors: Shi-You
authors: SY
authors: Chen
references: Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1385-95
references: 12816754
references: Curr Vasc Pharmacol. 2005 Jul;3(3):215-20
references: 16026318
references: J Cell Physiol. 2009 Nov;221(2):490-7
references: 19653255
references: Circulation. 1998 May 12;97(18):1848-67
references: 9603540
references: Atherosclerosis. 2008 Oct;200(2):229-38
references: 18490019
references: Heart. 2000 Apr;83(4):381-7
references: 10722532
references: Trends Microbiol. 2000 Sep;8(9):402-10
references: 10989307
references: Nan Fang Yi Ke Da Xue Xue Bao. 2009 Dec;29(12):2429-32
references: 20034894
references: N Engl J Med. 1977 May 5;296(18):1034-41
references: 321964
references: Free Radic Biol Med. 2009 Oct 1;47(7):941-52
references: 19577641
references: Nature. 2002 Jan 24;415(6870):389-95
references: 11807545
references: J Antimicrob Chemother. 2009 Jan;63(1):115-23
references: 18957395
references: Apoptosis. 2001 Aug;6(4):279-90
references: 11445670
references: Atherosclerosis. 2009 Nov;207(1):51-8
references: 19409565
references: Methods Enzymol. 1990;186:1-85
references: 2172697
references: Neuropathol Appl Neurobiol. 1995 Feb;21(1):3-9
references: 7770118
references: J Mol Cell Cardiol. 2003 Jul;35(7):861-5
references: 12818577
references: Mol Cells. 2009 Feb 28;27(2):159-66
references: 19277497
references: J Pharmacol Exp Ther. 2008 Apr;325(1):226-35
references: 18174384
references: Anal Biochem. 1976 May 7;72:248-54
references: 942051
references: Circulation. 2003 Oct 28;108(17):2034-40
references: 14581381
references: J Clin Invest. 1994 Oct;94(4):1621-8
references: 7929838
references: Toxicology. 2000 Nov 16;153(1-3):83-104
references: 11090949
references: Nat Biotechnol. 2001 Dec;19(12):1173-6
references: 11731788
references: Int J Biochem Cell Biol. 2007;39(4):787-98
references: 17306600
references: Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8856-61
references: 10922046
references: Diabetes. 2008 Jun;57(6):1446-54
references: 18511445
references: Int J Cardiol. 2010 Oct 8;144(2):315-7
references: 19332360
references: J Biol Chem. 1989 Nov 15;264(32):18890-5
references: 2553726
references: Tohoku J Exp Med. 2006 Nov;210(3):247-55
references: 17077602
references: Trends Mol Med. 2003 May;9(5):196-205
references: 12763524